BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
December 13, 2017 at 07:50 AM EST
* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS
